var data={"title":"Acetazolamide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Acetazolamide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5559?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=acetazolamide-drug-information\" class=\"drug drug_general\">see &quot;Acetazolamide: Drug information&quot;</a> and <a href=\"topic.htm?path=acetazolamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Acetazolamide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129795\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Diamox Sequels [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129796\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Acetazolam;</li>\n      <li>Diamox</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056202\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Carbonic Anhydrase Inhibitor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Diuretic, Carbonic Anhydrase Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44912647\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Metabolic alkalosis:</b> Limited data available; dosing regimens variable: PMA &ge;30 weeks: IV, Oral: 3 to 5 mg/kg/dose every 6 to 8 hours, commonly reported duration is 3 to 4 doses; most experience in patients with a PMA &ge;40 weeks using IV administration, dosing shown to significantly lower serum bicarbonate concentrations (Andrews 2013; Tam 2014);  another trial used 5 mg/kg/dose once daily for 3 doses with success in postcardiac surgery patients (age range: 8 days to 20 months) (Moffett 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056194\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=acetazolamide-drug-information\" class=\"drug drug_general\">see &quot;Acetazolamide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Altitude illness, acute:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prevention: Limited data available: Oral: Immediate release: Infants, Children, and Adolescents: 2.5 mg/kg/dose every 12 hours started either the day before (preferred) or on the day of ascent and may be discontinued after staying at the same elevation for 2 to 3 days or if descent initiated; maximum dose: 125 mg/dose (Luks 2010). <b>Note:</b> The International Society for Mountain Medicine does not recommend prophylaxis in children except in the rare circumstance of unavoidable rapid ascent or in children with known previous susceptibility to acute mountain sickness (Pollard 2001). Higher doses are effective up to 500 mg, but are also associated with increased adverse effects and not recommended (Luks 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Acute mountain sickness (AMS); moderate: Limited data available: Oral: Immediate release: 2.5 mg/kg/dose every 8 to 12 hours; maximum dose: 250 mg/dose. <b>Note:</b> With high altitude cerebral edema, dexamethasone is the primary treatment; however, acetazolamide may be used adjunctively with the same treatment dose (Luks 2010; Pollard 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Glaucoma:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;12 years: Limited data available: Oral: Immediate release: 10 to 30 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 1,000 mg/<b>day</b> (Portellos 1998; Sabri 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate release: Limited data available: 15 to 30 mg/kg/day in divided doses every 6 to 8 hours; maximum daily dose: 1,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended release (Diamox sequels):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling: 500 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate dosing: Weight-directed dosing: Limited data available: 15 to 30 mg/kg/day in divided doses twice daily; maximum daily dose: 1,000 mg/<b>day</b> (Pagliaro 2002; Sabri 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Edema:</b> Limited data available: Infants, Children, and Adolescents: Oral (immediate release), IV: 5 mg/kg/dose once daily or every other day in the morning (Park 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Epilepsy, short-term management:</b> Limited data available: Infants, Children, and Adolescents: Oral: Immediate release: Usual range: 4 to 16 mg/kg/day in 3 to 4 divided doses; may titrate; maximum daily dose: 30 mg/kg/<b>day</b> or 1,000 mg/<b>day</b> (whichever is less) (Reiss 1996); <b>Note:</b> Minimal additional benefit with doses &gt;16 mg/kg/day; <b>extended release capsule is not recommended for treatment of epilepsy</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Metabolic alkalosis:</b> Limited data available; dosing regimens variable: Infants, Children, and Adolescents: IV, Oral: 5 mg/kg/dose once daily for 3 doses been used in a prospective trial of postcardiac surgical patients (age range: 8 days to 20 months) and results showed a significant decrease in serum bicarbonate concentrations (Moffett 2007). A retrospective trial of 34 pediatric patients (mean age: 1.9 years; range: 18 days to 12 years) reported a mean effective dose of 5.4 mg/kg/dose every 6 to 8 hours; a trend showed every 6-hour dosing had a higher success rate but not statistically significant (Andrews 2013). In adults, the reported dosing is 500 mg as a single dose (Marik 1991; Moviat 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pseudotumor cerebri:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: Oral: Immediate release: Usual reported initial dose: 15 to 25 mg/kg/day in 2 to 3 divided doses; may increase if needed to a maximum daily dose: 100 mg/kg/<b>day</b> or 2,000 mg/<b>day</b> (whichever is less); therapy continued until resolution of headache, disc swelling, and visual field abnormalities; usually several months (eg, 3 to 9 months) (Distelmaier 2006; Hacifazlioglu 2012; Ko 2010; Per 2013; Rangwalla 2007; Soler 1998; Spennato 2011; Standridge 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral: Immediate release: Initial: 500 mg twice daily; may increase if needed; maximum daily dose: 4,000 mg/<b>day</b>; usual adult dose range: 1,000 to 4,000 mg/day in 2 to 4 divided doses (Phillips 2012; Standridge 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Glaucoma: </b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic simple (open-angle): 250 mg 1 to 4 times/day or 500 mg extended release capsule twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Secondary or acute (closed-angle): 250 to 500 mg; maintenance: 125 to 250 mg every 4 hours (250 mg every 12 hours has been effective in short-term treatment of some patients)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Edema:</b> Oral, IV: 250 to 375 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Epilepsy:</b> Oral: 8 to 30 mg/kg/day in divided doses. A lower dosing range of 4 to 16 mg/kg/day in 1 to 4 divided doses has also been recommended; maximum daily dose: 30 mg/kg/<b>day</b> or 1,000 mg/<b>day</b> (Oles 1989; Reiss 1996). <b>Note:</b> Minimal additional benefit with doses &gt;16 mg/kg/day; <b>extended release capsule is not recommended for treatment of epilepsy</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Altitude sickness:</b> Oral: 500 to 1,000 mg daily in divided doses every 8 to 12 hours (immediate release tablets) or divided every 12 to 24 hours (extended release capsules). These doses are associated with more frequent and/or increased side effects. Alternative dosing has been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prevention: 125 mg twice daily; beginning either the day before (preferred) or on the day of ascent; may be discontinued after staying at the same elevation for 2 to 3 days or if descent initiated (Basnyat 2006; Luks 2010). <b>Note:</b> In situations of rapid ascent (such as rescue or military operations), 1,000 mg/day is recommended by the manufacturer. The Wilderness Medical Society recommends consideration of using dexamethasone in addition to acetazolamide in these situations (Luks 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: 250 mg twice daily. <b>Note:</b> With high altitude cerebral edema, dexamethasone is the primary treatment; however, acetazolamide may be used adjunctively with the same treatment dose (Luks 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; acetazolamide is contraindicated in severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult: The following adjustments have been recommended (Aronoff 2007): Oral, IV: <b>Note:</b> Renally adjusted dose recommendations are based on doses of 250 mg every 6 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: No dosage adjustment recommended</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 50 mL/minute: Administer every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: Avoid use; contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Moderately dialyzable (20% to 50%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: Supplemental dose is not necessary (Schwenk 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> All patients: There are no dosage adjustments provided in the manufacturer's labeling; however, acetazolamide is contraindicated in patients with cirrhosis or severe liver impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129772\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 12 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diamox Sequels: 500 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg, 250 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129756\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056206\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with food to decrease GI upset; tablet may be crushed and suspended in cherry or chocolate syrup to disguise the bitter taste of the drug </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV:  Direct IV injection is the preferred parenteral route of administration. Specific IV push rates are not provided in the manufacturer's labeling. Some have recommended a maximum rate of 500 mg/minute (Gahart 2014).  Additionally, a study in adults to assess cerebrovascular reserve used a rapid IV push of up to 1 g over &le;1 minute (Piepgras 1990). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Not recommended as the drug's alkaline pH makes it very painful</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129789\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsules, tablets: Store at controlled room temperature. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Store reconstituted solutions for 3 days under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F), or 12 hours at room temperature, 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056205\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release tablets: Adjunct treatment of edema due to congestive heart failure, drug-induced edema, centrencephalic epilepsies, chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired (FDA approved in adults); prevention or amelioration of symptoms associated with acute mountain sickness (FDA approved in adults); treatment of metabolic alkalosis </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release capsules (Diamox Sequels): Adjunctive treatment of chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired (FDA approved in ages &ge;12 years and adults); prevention or amelioration of symptoms associated with acute mountain sickness (FDA approved in ages &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Adjunct treatment of edema due to congestive heart failure, drug-induced edema, centrencephalic epilepsies, chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired (FDA approved in adults); treatment of metabolic alkalosis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129850\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Acetazolamide may be confused with acetaminophen</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Diamox [Canada and multiple international markets] may be confused with Diabinese brand name for chlorpropamide [Multiple international markets]; Dobutrex brand name for dobutamine [Multiple international markets]; Trimox brand name for amoxicillin [Brazil]; Zimox brand name for amoxicillin [Italy] and carbidopa/levodopa [Greece]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129847\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Flushing </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Ataxia, confusion, convulsions, depression, dizziness, drowsiness, excitement, fatigue, flaccid paralysis, headache, malaise, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Allergic skin reaction, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Electrolyte imbalance, growth retardation (children), hyperglycemia, hypoglycemia, hypokalemia, hyponatremia, metabolic acidosis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Decreased appetite, diarrhea, dysgeusia, glycosuria, melena, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Crystalluria, hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic and oncologic: Agranulocytosis, aplastic anemia, leukopenia, thrombocytopenia, thrombocytopenic purpura </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Abnormal hepatic function tests, cholestatic jaundice, fulminant hepatic necrosis, hepatic insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Myopia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Auditory disturbance, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Polyuria, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129780\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to acetazolamide, sulfonamides, or any component of the formulation; marked hepatic disease or insufficiency; decreased sodium and/or potassium levels; adrenocortical insufficiency; cirrhosis; hyperchloremic acidosis; severe renal disease or dysfunction; long-term use in noncongestive angle-closure glaucoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although the FDA approved product labeling states this medication is contraindicated with other sulfonamide-containing drug classes, the scientific basis of this statement has been challenged. See &ldquo;Warnings/Precautions&rdquo; for more detail.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129760\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: Impairment of mental alertness and/or physical coordination may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfonamide (&ldquo;sulfa&rdquo;) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory acidosis: Use with caution in patients with respiratory acidosis; may worsen acidosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aspirin (high dose): Use with caution or avoid in patients taking high-dose aspirin concurrently; may lead to severe adverse effects including tachypnea, anorexia, lethargy, coma, and death. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly; may be more sensitive to side effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Increasing the dose does not increase diuresis and may increase the incidence of drowsiness and/or paresthesia; often results in a reduction of diuresis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; IM administration: Painful because of the alkaline pH of the drug; use by this route is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819721\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Growth retardation has been reported in children receiving chronic therapy (possibly due to chronic acidosis). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129837\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129765\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13213&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Indirect-Acting): Carbonic Anhydrase Inhibitors may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Carbonic Anhydrase Inhibitors may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): AcetaZOLAMIDE may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide: Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically, the risk for osteomalacia or rickets may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Carbonic Anhydrase Inhibitors may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: Carbonic Anhydrase Inhibitors may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Anticonvulsants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated.  If another combination is used, monitor patients closely for adverse effects.  Tachypnea, anorexia, lethargy, and coma have been reported.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Bicarbonate: AcetaZOLAMIDE may enhance the adverse/toxic effect of Sodium Bicarbonate. Specifically, the risk of renal calculus formation may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: Carbonic Anhydrase Inhibitor Diuretics may decrease the serum concentration of Trientine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129768\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129783\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies. Limited data is available following the use of acetazolamide in pregnant women for the treatment of idiopathic intracranial hypertension (Falardeau 2013; Kesler 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women exposed to acetazolamide during pregnancy for the treatment of seizure disorders are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at aedpregnancyregistry.org</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056201\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum electrolytes, CBC and platelet counts; intraocular pressure in glaucoma patients; monitor growth in pediatric patients </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129759\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reversible inhibition of the enzyme carbonic anhydrase resulting in reduction of hydrogen ion secretion at renal tubule and an increased renal excretion of sodium, potassium, bicarbonate, and water. Decreases production of aqueous humor and inhibits carbonic anhydrase in central nervous system to retard abnormal and excessive discharge from CNS neurons.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129779\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Capsule (extended release): 2 hours; Tablet (immediate release): 1 to 1.5 hours; IV: 2 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Capsule (extended release): 8 to 18 hours; IV: 15 minutes; Tablet: 2 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Inhibition of aqueous humor secretion: Capsule (extended release): 18 to 24 hours; IV: 4 to 5 hours; Tablet: 8 to 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Appears to be dose dependent; erratic with daily doses &gt;10 mg/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Erythrocytes, kidneys; blood-brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 95% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life: 2.4 to 5.8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Capsule (extended release): 3 to 6 hours; Tablet: 1 to 4 hours; IV: 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (70% to 100% [IV, tablet], 47% [extended release capsule] as unchanged drug within 24 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056212\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium content of 500 mg injection: 2.049 mEq </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129778\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 25 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;. Crush twelve 250 mg tablets in a mortar and reduce to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 60 days (Allen, 1996). When diluted in 120 mL solution of cherry syrup concentrate diluted 1:4 with simple syrup, NF, it is stable 60 days refrigerated (preferred) or at room temperature (Nahata, 2004).</p>\n    <div class=\"reference\">Allen LV Jr and Erickson MA 3rd, &quot;Stability of Acetazolamide, Allopurinol, Azathioprine, Clonazepam, and Flucytosine in Extemporaneously Compounded Oral Liquids,&quot; <i>Am J Health Syst Pharm</i>, 1996, 53(16):1944-9.<span class=\"pubmed-id\">8862208</span></div>\r\n\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129782\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, 12-hour</b> (AcetaZOLAMIDE ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $429.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (AcetaZOLAMIDE Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $49.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (AcetaZOLAMIDE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg (100): $217.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $288.31</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F129785\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acemox (BD);</li>\n      <li>Acetadiazol (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Acetak (PE);</li>\n      <li>Acetamide (LK);</li>\n      <li>Acetazol (KR);</li>\n      <li>Albox (JP);</li>\n      <li>Apo-Acetazolamide (MY);</li>\n      <li>Azol NCP (TW);</li>\n      <li>Azomid (ZA);</li>\n      <li>Carbinib (PT);</li>\n      <li>Cetamid (PH);</li>\n      <li>Defiltran (FR);</li>\n      <li>Diacarb (LV, RU, UA);</li>\n      <li>Diamox (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CO, CY, DK, EE, EG, FR, GB, GR, HK, HR, IE, IN, IQ, IR, IT, JO, JP, KR, KW, LB, LU, LY, MT, MY, NL, NO, NZ, OM, QA, RU, SA, SE, SG, SI, SK, SY, TH, VE, VN, YE, ZA);</li>\n      <li>Diamox Sustets (CO);</li>\n      <li>Diazomid (TR);</li>\n      <li>Diluran (CZ);</li>\n      <li>Diural (UY);</li>\n      <li>Diuramid (PL);</li>\n      <li>Diuremid (UA);</li>\n      <li>Edemox (ES);</li>\n      <li>Edimox (BD);</li>\n      <li>Evamox (PK);</li>\n      <li>Fonurit (HU);</li>\n      <li>Glaucomed (CO, EC);</li>\n      <li>Glaumox (AU, NZ);</li>\n      <li>Glaupax (CH, DE, HR, JP, TH);</li>\n      <li>Glauseta (ID);</li>\n      <li>Huma-Zolamide (HU);</li>\n      <li>Ledamox (JP);</li>\n      <li>Medene (TH);</li>\n      <li>Odemin (FI);</li>\n      <li>Optamide (PH);</li>\n      <li>Remox (BD);</li>\n      <li>Renamid (HR);</li>\n      <li>Stazol (PY);</li>\n      <li>Synomax (IN);</li>\n      <li>Theramox (BD);</li>\n      <li>Uramox (IL);</li>\n      <li>Zoladin (KR);</li>\n      <li>Zolmide (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Acetazolamide injection [prescribing information]. Schaumberg, IL: Sagent Pharmaceuticals; February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Acetazolamide tablets [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals U.S.A., Inc; March 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andrews MG, Johnson PN, Lammers EM, Harrison DL, Miller JL. Acetazolamide in critically ill neonates and children with metabolic alkalosis. <i>Ann Pharmacother</i>. 2013;47(9):1130-1135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/24259727 /pubmed\" target=\"_blank\" id=\"24259727 \">24259727 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, eds. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basnyat B, Gertsch JH, Holck PS, et al. Acetazolamide 125 mg BD is Not Significantly Different from 375 mg BD in the Prevention of Acute Mountain Sickness: The Prophylactic Acetazolamide Dosage Comparison for Efficacy (PACE) Trial. <i>High Alt Med Biol</i>. 2006;7(1):17-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/16544963/pubmed\" target=\"_blank\" id=\"16544963\">16544963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/15303450/pubmed\" target=\"_blank\" id=\"15303450\">15303450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diamox Sequels (acetazolamide) [prescribing information]. Pomona, NY: Duramed Pharmaceuticals, Inc; July 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Distelmaier F, Sengler U, Messing-Juenger M, et al. <i>Pseudotumor cerebri</i> as an important differential diagnosis of papilledema in children. <i>Brain and Development</i>. 2006;28:190-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/16368210/pubmed\" target=\"_blank\" id=\"16368210\">16368210</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Falardeau J, Lobb BM, Golden S, et al, &quot;The Use of Acetazolamide During Pregnancy in Intracranial Hypertension Patients,&quot; <i>J Neuroophthalmol</i>, 2013, 33(1):9-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/22635167/pubmed\" target=\"_blank\" id=\"22635167\">22635167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gahart BL, Nazareno AR. <i>2014 Intravenous Medications: A Handbook for Nurses and Health Professionals</i>. 30th ed. St Louis, MO: Elsevier/Mosby; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hacifazlioglu N, Yilmaz Y. <i>Pseudotumour cerebri</i> in children: etiological, clinical features and treatment modalities. <i>European Journal of Paediatric Neurology</i>. 2012;12:349-355.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/22050895/pubmed\" target=\"_blank\" id=\"22050895\">22050895</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in <i>Ann Pharmacother</i>. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/15644481/pubmed\" target=\"_blank\" id=\"15644481\">15644481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kesler A and Kupferminc M, &quot;Idiopathic Intracranial Hypertension and Pregnancy,&quot; <i>Clin Obstet Gynecol</i>, 2013, 56(2):389-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/23563883/pubmed\" target=\"_blank\" id=\"23563883\">23563883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ko MW,Liu GT. Pediatric idiopathic intracranial hypertension (<i>Pseudotumor cerebri</i>). <i>Horm Res Paediatr</i>. 2010;74:381-389.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/20962512/pubmed\" target=\"_blank\" id=\"20962512\">20962512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. <i>Wilderness Environ Med</i>. 2010;21(2):146-155.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/20591379/pubmed\" target=\"_blank\" id=\"20591379\">20591379</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik PE, Kussman BD, Lipman J, Kraus P. Acetazolamide in the treatment of metabolic alkalosis in critically ill patients. <i>Heart Lung</i>. 1991;20(5 Pt 1):455-459.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/1894525 /pubmed\" target=\"_blank\" id=\"1894525 \">1894525 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moffett BS, Moffett TI, Dickerson HA. Acetazolamide therapy for hypochloremic metabolic alkalosis in pediatric patients with heart disease. <i>Am J Ther</i>. 2007;14(4):331-335.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/17667206 /pubmed\" target=\"_blank\" id=\"17667206 \">17667206 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moviat M, Pickkers P, van der Voort PH, van der Hoeven JG. Acetazolamide-mediated decrease in strong ion difference accounts for the correction of metabolic alkalosis in critically ill patients. <i>Crit Care</i>. 2006;10(1):R14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/16420662 /pubmed\" target=\"_blank\" id=\"16420662 \">16420662 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oles KS, Penry JK, Cole DLW, et al, &ldquo;Use of Acetazolamide as an Adjunct to Carbamazepine in Refractory Partial Seizures,&rdquo; <i>Epilepsia</i>, 1989, 30(1):74-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/2492225/pubmed\" target=\"_blank\" id=\"2492225\">2492225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pagliaro LA and Pagliaro AM, eds. <i>Problems in Pediatric Drug Therapy.</i>4th ed. Washington, DC: American Pharmaceutical Association; 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Per H, Canpolat M, Gumus H, et al. Clinical spectrum of the <i>pseudotumor cerebri</i> in children: etiological, clinical features, treatment and prognosis. <i>Brain Dev</i>. 2013;35:561-568.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/22981259/pubmed\" target=\"_blank\" id=\"22981259\">22981259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips PH. Pediatric pseudotumor cerebri.<i> Int Ophthalmol Clin</i>. 2012;52(3):51-59, xii.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/22668539 /pubmed\" target=\"_blank\" id=\"22668539 \">22668539 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Piepgras A, Schmiedek P, Leinsinger G, Haberl RL, Kirsch CM, Einh&auml;upl KM. A simple test to assess cerebrovascular reserve capacity using transcranial Doppler sonography and acetazolamide. <i>Stroke</i>. 1990;21(9):1306-1311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/2204147 /pubmed\" target=\"_blank\" id=\"2204147 \">2204147 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pollard AJ, Niermeyer S, Barry P, et al, &ldquo;Children at High Altitude: An International Consensus Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001,&rdquo; <i>High Alt Med Biol</i>, 2001, 2(3):389-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/11682018/pubmed\" target=\"_blank\" id=\"11682018\">11682018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Portellos M, Buckley EG, Freedman SF. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. <i>J AAPOS</i>. 1998;2(1):43-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/10532366/pubmed\" target=\"_blank\" id=\"10532366\">10532366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rangwala LM, Liu GT. Pediatric idiopathic intracranial hypertension. <i>Survey of Ophthalmology</i>. 2007;52(6):597-617.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/18029269/pubmed\" target=\"_blank\" id=\"18029269\">18029269</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reiss WG and Oles KS, &ldquo;Acetazolamide in the Treatment of Seizures,&rdquo; <i>Ann Pharmacother</i>, 1996, 30(5):514-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/8740334 /pubmed\" target=\"_blank\" id=\"8740334 \">8740334 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sabri K, Levin AV. The additive effect of topical dorzolamide and systemic acetazolamide in pediatric glaucoma.<i> J AAPOS</i>. 2006;10(5):464-468.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/17070484/pubmed\" target=\"_blank\" id=\"17070484\">17070484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    S&ouml;derman P, Hartvig P, and Fagerlund C, &quot;Acetazolamide Excretion Into Human Breast Milk,&quot; <i>Br J Clin Pharmacol</i>, 1984, 17(5):599-600.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/6733009/pubmed\" target=\"_blank\" id=\"6733009\">6733009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soler D, Cox T, Bullock P, et al. Diagnosis and management of benign intracranial hypertension. <i>Arch Dis Child</i>. 1998;78:89-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/9534686/pubmed\" target=\"_blank\" id=\"9534686\">9534686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7999862\"></a>Schwenk MH, Blaustein DA, Wagner JD. The pharmacokinetics of acetazolamide during CAPD. <i>Adv Perit Dial.</i> 1994;10:44-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/7999862/pubmed\" target=\"_blank\" id=\"7999862\">7999862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwenk MH, St. Peter WL, Meese MG, et al. Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis. <i>Pharmacotherapy</i>. 1995;15(4):522-527.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/7479208/pubmed\" target=\"_blank\" id=\"7479208\">7479208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/15242722/pubmed\" target=\"_blank\" id=\"15242722\">15242722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spennato P, Ruggiero C, Parlato RS, et al. <i>Pseudotumor cerebri</i>. <i>Childs Nerv Syst</i>. 2011;27:215-235.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/20721668/pubmed\" target=\"_blank\" id=\"20721668\">20721668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Standridge S. Idiopathic intracranial hypertension in children: a review and algorithm. <i>Pediatric Neurology</i>. 2010;43(6): 377-390.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/21093727/pubmed\" target=\"_blank\" id=\"21093727\">21093727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tam B, Chhay A, Yen L, Tesoriero L, Ramanathan R, Seri I, Friedlich PS. Acetazolamide for the management of chronic metabolic alkalosis in neonates and infants. <i>Am J Ther</i>. 2014;21(6):477-481.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/23011176 /pubmed\" target=\"_blank\" id=\"23011176 \">23011176 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetazolamide-pediatric-drug-information/abstract-text/15373844/pubmed\" target=\"_blank\" id=\"15373844\">15373844</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13213 Version 165.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F129795\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F129796\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1056202\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F44912647\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1056194\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F129772\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F129756\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1056206\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F129789\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1056205\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F129850\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F129847\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F129780\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F129760\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819721\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F129837\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F129765\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F129768\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F129783\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1056201\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F129759\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F129779\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1056212\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F129778\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F129782\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F129785\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13213|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=acetazolamide-drug-information\" class=\"drug drug_general\">Acetazolamide: Drug information</a></li><li><a href=\"topic.htm?path=acetazolamide-patient-drug-information\" class=\"drug drug_patient\">Acetazolamide: Patient drug information</a></li></ul></div></div>","javascript":null}